CpG oligodeoxynucleotides promote the host protective response against infection with Cryptococcus neoformans through induction of interferon-gamma production by CD4+ T cells

Clinical and Experimental Immunology

Volumn 140, Issue 2, 2005, Pages 220-229

  Miyagi, K ^a   Kawakami, K ^a   Kinjo, Y ^a,b   Uezu, K ^a   Kinjo, T ^a   Nakamura, K ^a   Saito, A ^a  

^a UNIVERSITY OF THE RYUKYUS   (Japan)

^b LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

CpG DNA; Cryptococcus neoformans; Lung; Th1 Th2 balance

Indexed keywords

BACTERIAL ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 4; NEUTRALIZING ANTIBODY; OLIGODEOXYNUCLEOTIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INFECTION; CONTROLLED STUDY; CPG ISLAND; CRYPTOCOCCUS NEOFORMANS; CYTOKINE PRODUCTION; CYTOKINE RELEASE; FUNGAL VIRULENCE; FUNGUS GROWTH; HOST RESISTANCE; LUNG INFECTION; LUNG LAVAGE; LYMPH NODE CELL; LYMPHOCYTE DIFFERENTIATION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; T CELL DEPLETION; TH1 CELL; TH2 CELL;

ANIMALS; BRONCHOALVEOLAR LAVAGE FLUID; CELLS, CULTURED; CRYPTOCOCCOSIS; IMMUNITY, CELLULAR; INTERFERON TYPE II; LUNG; LUNG DISEASES, FUNGAL; LYMPH NODES; MICE; OLIGODEOXYRIBONUCLEOTIDES; TH1 CELLS; TH2 CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 17644384554     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2005.02772.x     Document Type: Article

References (51)

1. Stevens DA. Fungal infections in AIDS patients. Br J Clin Pract Suppl 1990; 71:11-22.
2. Lim TS, Murphy JW. Transfer of immunity to cryptococcosis by T-enriched splenic lymphocytes from Cryptococcus neoformans-sensitized mice. Infect Immun 1980; 30:5-11.
3. Koguchi Y, Kawakami K. Cryptococcal infection and Th1-Th2 cytokine balance. Int Rev Immunol 2002; 21:423-38.
4. Yuan RR, Casadevall A, Oh J, Scharff MD. T cells cooperate with passive antibody to modify Cryptococcus neoformans infection in mice. Proc Natl Acad Sci USA 1997; 94:2483-8.
5. Decken K, Kohler G, Palmer-Lehmann K et al. Interleukin-12 is essential for a protective Th1 response in mice infected with Cryptococcus neoformans. Infect Immun 1998; 66:4994-5000.
6. Kawakami K, Koguchi Y, Qureshi MH et al. Reduced host resistance and Th1 response to Cryptococcus neoformans in interleukin-18 deficient mice. FEMS Microbiol Lett 2000; 186:121-6.
7. Kawakami K, Koguchi Y, Qureshi MH et al. IL-18 contributes to host resistance against infection with Cryptococcus neoformans in mice with defective IL-12 synthesis through induction of IFN-γ production by NK cells. J Immunol 2000; 165:941-7.
8. Rayhane N, Lortholary O, Fitting C et al. Enhanced sensitivity of tumor necrosis factor/lymphotoxin-α-deficient mice to Cryptococcus neoformans infection despite increased levels of nitrite/nitrate, interferon-γ, and interleukin-12. J Infect Dis 1999; 180:1637-47.
9. Blackstock R, Buchanan KL, Adesina AM, Murphy JW. Differential regulation of immune responses by highly and weakly virulent Cryptococcus neoformans isolates. Infect Immun 1999; 67:3601-9.
10. Kawakami K, Tohyama M, Teruya K, Kudeken N, Xie Q, Saito A. Contribution of interferon-γ in protecting mice during pulmonary and disseminated infection with Cryptococcus neoformans. FEMS Immunol Med Microbiol 1996; 13:123-30.
11. Kawakami K, Tohyama M, Xie Q, Saito A. IL-12 protects mice against pulmonary and disseminated infection caused by Cryptococcus neoformans. Clin Exp Immunol 1996; 104:208-14.
12. Kawakami K, Qureshi MH, Zhang T, Okamura H, Kurimoto M, Saito A. IL-18 protects mice against pulmonary and disseminated infection with Cryptococcus neoformans by inducing IFN-γ production. J Immunol 1997; 159:5528-34.
13. Kawakami K, Qifeng X, Tohyama M, Qureshi MH, Saito A. Contribution of tumour necrosis factor-α (TNF-α) in host defence mechanism against Cryptococcus neoformans. Clin Exp Immunol 1996; 106:468-74.
14. Tokunaga T, Yamamoto H, Shimada S et al. Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity. J Natl Cancer Inst 1984; 72:955-62.
15. Yamamoto S, Kuramoto E, Shimada S, Tokunaga T. In vitro augmentation of natural killer cell activity and production of interferon-α/beta and -γ with deoxyribonucleic acid fraction from Mycobacterium bovis BCG. Jpn J Cancer Res 1988; 79:866-73.
16. Tokunaga T, Yamamoto T, Yamamoto S. How BCG led to the discovery of immunostimulatory DNA. Jpn J Infect Dis 1999; 52:1-11.
17. Messina JP, Gilkeson GS, Pisetsky DS. Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA. J Immunol 1991; 147:1759-64.
18. Krieg AM, Yi AK, Matson S et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995; 374:546-9.
19. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002; 20:709-60.
20. Jakob T, Walker PS, Krieg AM, Udey MC, Vogel JC. Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides. a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. J Immunol 1998; 161:3042-9.
21. Sparwasser T, Koch ES, Vabulas RM et al. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur J Immunol 1998; 28:2045-54.
22. Schulz O, Edwards AD, Schito M et al. CD40 triggering of heterodimeric IL-12 p70 production by dendritic cells in vivo requires a microbial priming signal. Immunity 2000; 13:453-62.
23. Klinman DM, Yi AK, Beaucage SL, Conover J, Krieg AM. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci USA 1996; 93:2879-83.
24. Lipford GB, Sparwasser T, Zimmermann S, Heeg K, Wagner H. CpG-DNA-mediated transient lymphadenopathy is associated with a state of Th1 predisposition to antigen-driven responses. J Immunol 2000; 165:1228-35.
25. Krieg AM, Love-Homan L, Yi AK, Harty JT. CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge. J Immunol 1998; 161:2428-34.
26. Elkins KL, Rhinehart-Jones TR, Stibitz S, Conover JS, Klinman DM. Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria. J Immunol 1999; 162:2291-8.
27. Zimmermann S, Egeter O, Hausmann S et al. CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis. J Immunol 1998; 160:3627-30.
28. Walker PS, Scharton-Kersten T, Krieg AM et al. Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-γ-dependent mechanisms. Proc Natl Acad Sci USA 1999; 96:6970-5.
29. Gramzinski RA, Doolan DL, Sedegah M, Davis HL, Krieg AM, Hoffman SL. Interleukin-12- and gamma interferon-dependent protection against malaria conferred by CpG oligodeoxynucleotide in mice. Infect Immun 2001; 69:1643-9.
30. Kawakami K, Kohno S, Morikawa N, Kadota J, Saito A, Hara K. Activation of macrophages and expansion of specific T lymphocytes in the lungs of mice intratracheally inoculated with Cryptococcus neoformans. Clin Exp Immunol 1994; 96:230-7.
31. Kawakami K, Tohyama M, Qifeng X, Saito A. Expression of cytokines and inducible nitric oxide synthase mRNA in the lungs of mice infected with Cryptococcus neoformans: effects of interleukin-12. Infect Immun 1997; 65:1307-12.
32. Cowdery JS, Chace JH, Yi AK, Krieg AM. Bacterial DNA induces NK cells to produce IFN-γ in vivo and increases the toxicity of lipopolysaccharides. J Immunol 1996; 156:4570-5.
33. Iho S, Yamamoto T, Takahashi T, Yamamoto S. Oligodeoxynucleotides containing palindrome sequences with internal 5′-CpG-3′ act directly on human NK and activated T cells to induce IFN-γ production in vitro. J Immunol 1999; 163:3642-52.
34. Murphy JW, MacDaniel DO. In vitro reactivity of natural killer (NK) cells on Cryptococcus neoformans. J Immunol 1982; 128:1577-83.
35. Lipscomb MF, Alvarellos T, Toews GB et al. Role of natural killer cells in resistance to Cryptococcus neoformans infections in mice. Am J Pathol 1991; 128:354-61.
36. Hidore MR, Nabavi N, Sonleitner F, Murphy JW. Murine natural killer cells are fungicidal to Cryptococcus neoformans. Infect Immun 1991; 59:1747-54.
37. Kawakami K, Koguchi Y, Qureshi MH et al. NK cells eliminate Cryptococcus neoformans by potentiating the fungicidal activity of macrophages, rather than by directly killing them, upon stimulation with IL-12 and IL-18. Microbiol Immunol 2000; 44:1043-50.
38. Kawakami K, Kinjo Y, Uezu K et al. Monocyte chemoattractant protein-1-dependent increase of Vα14 NKT cells in lungs and their roles in Th1 response and host defense in cryptococcal infection. J Immunol 2001; 167:6525-32.
39. Uezu K, Kawakami K, Miyagi K et al. Accumulation of γδ T cells in the lungs and their regulatory roles in Th1 response and host defense against pulmonary infection with Cryptococcus neoformans. J Immunol 2004; 172:7629-34.
40. Qureshi MH, Zhang T, Koguchi Y et al. Combined effects of IL-12 and IL-18 on the clinical course and local cytokine production in murine pulmonary infection with Cryptococcus neoformans. Eur J Immunol 1999; 29:643-9.
41. Sun S, Zhang X, Tough DF, Sprent J. Type I interferon-mediated stimulation of T cells by CpG DNA. J Exp Med 1998; 188:2335-42.
42. Lipford GB, Bauer M, Blank C, Reiter R, Wagner H, Heeg K. CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants. Eur J Immunol 1997; 27:2340-4.
43. Wagner H. Bacterial CpG DNA activates immune cells to signal infectious danger. Adv Immunol 1999; 73:329-68.
44. + T cell responses and protection against leishmania major infection. J Exp Med 2002; 195:1565-73.
45. + T cells in protection. Cancer Res 2002; 62:7234-40.
46. Havell EA. Role of TNF in resistance to bacteria. Immunol Series 1992; 56:341-63.
47. Huffnagle GB, Toews GB, Burdick MD et al. Afferent phase production of TNF-α is required for the development of protective T cell immunity to Cryptococcus neoformans. J Immunol 1996; 157:4529-36.
48. Herring AC, Lee J, McDonald RA, Toews GB, Huffnagle GB. Induction of interleukin-12 and gamma interferon requires tumor necrosis factor alpha for protective T1-cell-mediated immunity to pulmonary Cryptococcus neoformans infection. Infect Immun 2002; 70:2959-64.
49. Kwon HJ, Lee KW, Yu SH, Han JH, Kim DS. NF-κB-dependent regulation of tumor necrosis factor-α gene expression by CpG-oligodeoxynucleotides. Biochem Biophys Res Commun 2003; 31:129-38.
50. Shoda LK, Kegerreis KA, Suarez CE, Mwangi W, Knowles DP, Brown WC. Immunostimulatory CpG-modified plasmid DNA enhances IL-12, TNF-α, and NO production by bovine macrophages. J Leukoc Biol 2001; 70:103-12.
51. Agrawal S, Kandimalla ER. Medicinal chemistry and therapeutic potential of CpG DNA. Trends Mol Med 2002; 8:114-21.